Tuesday , November 21 2017
Home / Resources / Polls / Survey Says: Top Polls of 2016

Survey Says: Top Polls of 2016

In a year that saw much discussion about new drugs, new devices, and how politics might affect medical care, the surveys Diabetes in Control readers were most interested in were those that touched on the core aspects of care for patients with diabetes.

1. How often do you recommend an A1c test for your type 1 patients? (Issue 833, May 14, 2016)

Overwhelmingly, our readers indicated “every three months” as their recommendation, with “every 6 months” a distant second. “Every month” trailed far behind in third, and just one user indicated “yearly” as their preferred option.

2. What do you feel is the primary reason for the high cost of insulin? (Issue 856, Oct. 22, 2016)

Just over half of you selected the simple answer “Greed.” The second and third place results — which accounted for most of the remaining responses — were “Stockholders Needing a Return on Investment” and “Corporate Salaries.” Just a handful of readers thought “Research and Development” were a primary factor in costs.

3. If you could have any A1c result regardless of your health, even if you don’t have diabetes, what A1c number would you like to have? (Issue 826, March 26, 2016)

The vast majority of you chose “<5%” as your ideal A1c result. “<6%” and “6%” finished in second and third.

4. What do you recommend to your patients as the first choice to treat hypoglycemia? (Issue 859, November 12, 2016)

“Glucose tablets,” was the majority choice. “Juice, soda or milk,” was selected by just under a third of you, with “Glucose gel or liquid” taking third place in the results.

5. Will you consider switching over your Lantus users to Lilly’s new basal insulin Basaglar, which is not approved as a biosimilar product, but has the same exact properties as Lantus and will likely be less expensive? (Issue 814, January 2, 2016)

Our very first survey of 2016 was the only question pertaining to a new product to crack the top 5. More than half of respondents expressed willingness to switch patients to Basaglar, with the rest of you almost equally divided between a firm “no” and “not sure.”